Oncology Medical News about Head and Neck Cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor
Chemotherapy, 08/07/09

Shin HC et al. - In a study to we investigated the antitumor effect and differentially expressed genes (DEGs) in head and neck cancer (HNC) cells treated by a novel CDK inhibitor, 2-[1,1'-biphenyl]- 4-yl-N-[5-(1,1-dioxo-16-isothiazolidin-2-yl)-1H-indazol-3-yl] acetamide (BAI), these results indicate that BAI has strong anticancer activities on HNC cells, and the DEGs induced by BAI may become involved in BAI-induced cancer cell death.

Methods

Cell growth was measured by XTT assay.
Cell cycle and apoptosis were determined using flow cytometry.
GeneFishing PCR was utilized to identify DEGs; protein expression was analyzed by Western blot.

Results

Exposure to BAI of 2 different HNC cell lines, AMC-HN4 and AMC-HN6, induced apoptosis in association with growth inhibition, cell cycle arrest, caspase-3 activation, and cytochrome c release.
Data from GeneFishing PCR experiments demonstrated 10 DEGs in AMC-HN6 cells treated with BAI.
Some of these DEGs turned out to encode proteins with functions related to key cellular processes.

<< Previous
Association between genetic polymorphism in DNA repair genes and...

Next >>
Increased serum hepcidin-25 level and increased tumor expression...